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Abstract
Background: To report about early clinical experience in radiation treatment of head and neck cancer of different
sites and histology by volumetric modulated arcs with the RapidArc technology.
Methods: During 2009, 45 patients were treated at Istituto Clinico Humanitas with RapidArc (28 males and 17
females, median age 65 years). Of these, 78% received concomitant chemotherapy. Thirty-six patients were treated
as exclusive curative intent (group A), three as postoperative curative intent (group B) and six with sinonasal
tumours (group C). Dose prescription was at Planning Target Volumes (PTV) with simultaneous integrated boost:
54.45Gy and 69.96Gy in 33 fractions (group A); 54.45Gy and 66Gy in 33 fractions (group B) and 55Gy in 25 fractions
(group C).
Results: Concerning planning optimization strategies and constraints, as per PTV coverage, for all groups, D98% >
95% and V95% > 99%. As regards organs at risk, all planning objectives were respected, and this was correlated
with observed acute toxicity rates. Only 28% of patients experienced G3 mucositis, 14% G3 dermitis 44% had G2
dysphagia. Nobody required feeding tubes to be placed during treatment. Acute toxicity is also related to
chemotherapy. Two patients interrupted the course of radiotherapy because of a quick worsening of general
clinical condition.
Conclusions: These preliminary results stated that volumetric modulated arc therapy in locally advanced head and
neck cancers is feasible and effective, with acceptable toxicities.
Introduction
Radiotherapy (RT), with or without chemotherapy, is the
primary treatment modality for head and neck cancer
patients. In the last decade intensity modulated radio-
therapy (IMRT) has gradually assumed a wide role in
the management of such diseases. IMRT has the advan-
tage, over the previously used conformal therapy, of
improving normal tissue and organ sparing together
with good target coverage. The clear dosimetric benefits
were translated to better clinical results in terms of
reduction of toxicity, which can improve the quality of
life of patient receiving RT, without compromising the
probability of tumour control.
Reviews for treatment outcome and major toxicity
patterns can be found in Gregoire et al (1), Lee et al (2)
and in Popovtzer et al (3) and in references therein. On
the toxicity side, besides the attention given to spinal
cord and brain stem (with toxicity thresholds of 45-50
Gy for the first and at 50 Gy for the second in most of
the investigations), it is consolidated knowledge that, for
parotids, mean doses inferior to 25-30 Gy correlate well
with substantial recovery of function within two years
(Li et al (4), Deasy et al (5)). Higher thresholds were
o b s e r v e df o rs u b - m a n d i b u l a rg l a n d si nt h er a n g eo f3 9
Gy by Murdoc et al (6), while a dose to oral cavity of
about 30Gy for late mucositis was reported by Narayan
et al (7). Recently, the wide application of IMRT allowed
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mon toxicity patterns. As an example, the reduction of
dysphagia was correlated by Feng et al (8) and Levendag
et al (9) with the irradiation of the swallowing structures
as the constrictor muscles.
The same high treatment quality is achievable today
with other treatment techniques, as the rather new volu-
metric modulated arc therapy. One of these solutions is
the RapidArc
(r) implementation (Varian Medical System,
Palo Alto, CA, USA). Based on the original investigation
of K. Otto (10), RapidArc
(r) was recently introduced in
clinical practice in several institutes after an intensive
validation at planning level where it was compared to
IMRT or other approaches, in a series of studies on var-
ious indications (11-20).
RapidArc was also explored for head and neck
patients (19-21) demonstrating a dosimetric improve-
ment with respect to the most commonly used IMRT
for organs at risk sparing, especially when using two
arcs.
At the Istituto Clinico Humanitas, since January 2009,
all head and neck patients are treated with RapidArc
technology, generally associated with chemotherapy.
Aim of the present study is to evaluate the initial clinical
experience with head and neck RapidArc patients, in
terms of dosimetric analysis and acute toxicity results.
Methods and materials
Patients’ selection
This is a single-Institute non randomised retrospective
study. Between January and December 2009, 45 patients
presenting head and neck tumours, were treated with
RapidArc at Istituto Clinico Humanitas. Table 1 shows
the descriptive data of the group of patients; this is not
a homogeneous cohort, indicating that the aim of the
study is to report about early experiences in head and
neck with RapidArc, not focussing on specific outcome
or toxicity in single subgroups. It includes 28 male and
17 female with a median age of 65 years (range: 28-96
years). The primary sites of disease were oropharynx,
larynx and oral cavity. Eleven patients presented a histo-
logical type different from squamous cell carcinoma
(SCC). Of the SCC patients, 5 presented with stage III,
27 with stage IVA, 1 with stage IVB. Six SCC patients
presented a T1/T2 stage and 27 a T3/T4 stage. Consid-
ering N parameter in the SCC group, one patient was
N0, six patients showed N1 stage, 25 patients showed
N2, one patient presented N3. None showed distant
metastases. Each patient underwent a pre-treatment eva-
luation, including a complete history and physical exam-
ination, magnetic resonance imaging of head and neck
region, direct flexible fibre optic endoscopic examina-
tion, chest X-ray or thoracic computed tomography
(CT). Positron emission tomography (18-FDG-PET)
scans were performed in 6 patients.
Patients were stratified into three groups:
- Group A: 36 patients treated with exclusive curative
intent.
- Group B: 3 patients treated in a postoperative
regimen.
- Group C: 6 patients presenting sinonasal tumours.
Thirty-five patients received concurrent chemotherapy
(ChT): 16 with CDDP 100 mg/mq, day 1, 22, 43 of
radiation treatment, and 19 patients with Cetuximab. In
patient receiving Cetuximab, administration was
initiated one week before RT at loading dose of 400 mg/
mq of body surface area over a period of 120 minutes,
followed by weekly 60 minute infusion of 250/mq dur-
ing RT.
Volumes definition and dose prescription
A CT scan was performed for each patient with adjacent
3 mm slices. Patients were scanned in supine position,
with personalized head mask.
Table 1 Summary of patients characteristics at
treatment start
Number of patients 45
Site Oral Cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal Cavity and Paranasal
Sinuses
Other
7
3
16
1
10
6
2
Histology Squamous cell carcinoma
Differentiated carcinoma
Undifferentiated carcinoma
Adenoidocistic carcinoma
Estesioneuroblastoma
Sarcomas
34
1
2
3
3
2
Sex Males
Females
28
17
Age
Performance Status
Median [range]
PS 0
PS 1
PS 2
65 [28, 96]
y.o.
28
11
6
Diagnostic imaging PET
RM
6
45
Stage II
III
IV
4
8
33
Chemotherapy No ChT
CDDP
Cetuximab
10
16
19
Radiation Dose
Prescription
Group A: 69.96/54.45Gy in 33
fractions
Group B: 66.0/54.45 Gy in 33
fractions
Group C: 55Gy in 25 fractions
36
3
6
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Page 2 of 10The Gross Tumour Volume (GTV) was defined as the
gross extent of tumour shown by imaging, including all
involved (positive) lymph nodes. MRI, and in few cases
FDG-PET, were used in the delineation of GTV. On the
basis of the primary tumour size and involved nodes,
the high-risk Clinical Target Volume (CTV1) was
defined as GTV (guided by clinical criteria and FDG-
PET imaging whenever available) plus a margin for
microscopic spread, and the low-risk Clinical Target
Volume (CTV2) included precautionally uninvolved
nodes. A margin for Planning Target Volume (PTV)
was generated by expanding the CTV by 3 mm in all
directions except 6 mm in the cranio-caudal direction.
Organs at risk (OAR) were contoured by the planner
and included as follow: spinal cord, brain stem, left and
right parotids; larynx and uninvolved oral cavity were
outlined whenever not heavily included in the target.
Whenever close to the PTV, also left and right eyes,
optic nerves, and optic chiasm were drawn. In addition,
the Healthy Tissue was defined as the patient’sv o l u m e
included in the CT dataset minus all PTV volumes.
Dose was prescribed to mean PTV dose for the high
dose level as follows:
- Group A: SIB (Simultaneous Integrated Boost) with
two dose levels of 54.45Gy and 69.96Gy in 33 frac-
tions (1.65 and 2.12Gy/fraction, respectively). Six of
the 36 patients in this group received a three dose
level treatment, with an intermediate level of 59.4Gy
(1.8Gy/fraction), of limited volume. In the present
study this intermediate target was not analyzed.
- Group B: SIB with two dose levels of 54.45Gy and
66Gy in 33 fractions (1.65 and 2Gy/fraction,
respectively).
- Group C: single dose level of 55Gy in 25 fractions
(2.2Gy/fraction).
All patients were treated once a day, 5 days a week.
Plans were optimized for one or two isocentric arcs
for a Clinac 2100 equipped with a Millennium-120MLC
and beam energy of 6MV. Maximum Dose Rate was set
to 600MU/min. Further details on RapidArc technique
can be found for example in (12,15).
RapidArc plan optimization (with Progressive Resolu-
tion Optimizer II implemented in the Eclipse treatment
planning system) was performed requiring PTV coverage
of 95%-107%. Concerning OARs the objectives were as
following: Spinal cord: D1% < 46Gy; Brain stem: D1% <
54Gy; Parotids (considered separately left and right):
V30Gy < 45%, Dmean <2 6 G y ;L a r y n x :V 40Gy < 50%; Oral
cavity (not involved): V40Gy <5 0 % ;E y e s :V 40Gy <5 0 % ;
Optic nerves and Chiasm: D1% < 50Gy. A general strategy
was followed during the optimisation process, setting, as
priorities, higher values to targets with respect to organs
a tr i s k .I na d d i t i o nt ot h ed e f i n e do r g a n sa tr i s k ,a
dummy structure drawn as a shell around the targets was
used to confine the dose inside the PTV forcing the sur-
rounding healthy tissues to receive lower doses.
All dose distributions were computed with the Aniso-
tropic Analytical Algorithm (AAA, version 8.6) imple-
mented in the Eclipse planning system with a calculation
grid resolution of 2.5 mm.
Daily check of patient positioning was performed for
all patients by means of kV-cone beam CT (CBCT) sys-
tem integrated in the machine.
Data evaluation
Plan quality was analyzed from Dose Volume Histogram
(DVH) data.
PTV and CTV (high and low dose levels) coverage was
scored through D2% (maximum significant dose), D98%
(minimum significant dose), V95%,V 107%; homogeneity
was defined as D5%-D95%. Dose distribution conformity
to PTV was scored as Conformity Index (CI95%), defined
as the ratio between the patient’s volume receiving at
least 95% of the dose prescription, and the volume of
related PTV; CI95% was reported for both high and low
dose PTVs. Target data analysis was conducted for each
group separately.
Concerning OARs, the mean dose, the maximum dose
(as D1%) and appropriate values of VxGy (volume receiv-
ing at least x Gy) were analyzed, but only findings rela-
tive to the plan objectives were reported. About Healthy
Tissue, similar parameters were analyzed. To account
for hot spots, the External Volume Index (EI) was
defined as 100*VD/VPTV,w h e r eV D i st h ev o l u m eo f
Healthy Tissue receiving more than the prescribed low
dose, and VPTV is the volume of all PTV. All dosimetric
data were reported as average over all the patients (or
patients belonging to a specific group); errors refer to
one standard deviation. OARs data of Group A and B
were analyzed together; presenting irradiation of similar
anatomical regions, while Group C was kept separated
involving the sinonasal region only, and not the neck
areas.
Technical delivery parameters of RapidArc treatments
are reported, as well as the beam-on time (defined with-
out inclusion of patient positioning and imaging
procedures).
Results of pre-treatment plan quality assurance are
reported as Gamma Agreement Index (GAI), defined as
the percentage of modulated field area passing the
g-index criteria with thresholds on dose difference ΔD=
3% of the significant maximum dose, and on Distance
to Agreement DTA = 3 mm. Measurements and analysis
were performed by means of the GLAaS methodology
described in (22,23) based on absorbed dose to water
derived from EPID measurements.
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All patients were evaluated weekly during the RT course
and after the completion of the treatment with a prede-
fined follow-up schedule. The here reported data refer
to acute toxicity at the end of RT, scored in terms of
mucositis, radiation dermitis and dysphagia, according
to the Common Terminology Criteria for Adverse
Events (CTCAEv3.0) system developed by the National
Cancer Institute.
Toxicity data were stratified in Group A+B and Group
C due to the different treatment localization, and also
for chemotherapy (CDDP, Cetuximab, no chemother-
apy) in order to not mix up toxicity coming from the
combination of chemo-radiation treatment (e.g. it is
known the high skin toxicity when Cetuximab is
administered).
Results
Dosimetric and technical results
Figure 1 shows examples of dose distributions for one
patient of Group A and one patient of Group C in axial,
coronal and sagittal views. CTVs, PTVs and main OARs
are shown as solid lines. Figure 2 presents the mean
DVHs for CTV and PTV stratified as high and low dose
(targets of patients of Group C are included in the high
dose volumes), while Figure 3 reports mean DVHs for
OARs and Healthy Tissue, stratified in Group A+B and
Group C. Dotted lines represent inter-patient variability
at one standard deviation. In figure 2, second row, a bet-
ter dose homogeneity in the low dose target (both PTV
and CTV) is shown for group B with respect to group
A. This variation could be ascribed to the relative differ-
ence between the two specific dose levels (being
54.45Gy the low dose, 69.96Gy and 66Gy for the high
dose in group A and B, respectively): the larger the dif-
ference, the more pronounced the DVH tail to higher
doses.
Findings from the DVH analysis are reported in Table
2 for targets (CTV and PTV); while in table 3 OARs
and Healthy Tissue are presented, including the specific
planning objectives.
Dosimetric data showed a good sparing of OARs as
well as good target coverage, with respect to planning
objectives for all the included parameters.
The target volume receiving at least 95% of the pre-
scribed dose is higher than 97% for group A and B,
while slightly less for group C, due probably to the
higher tissue inhomogeneity in ethmoidal regions (with
Figure 1 Dose distributions for two patients (upper row from Group A, lower row from Group C) for axial, coronal and sagittal views.
CTV, PTV, and OARs are outlined.
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value of the CTV is higher than 99%.
As regards OARs, the serial organs as spinal cord and
brain stem never reached the tolerance level, being the
average value of maximum dose well below the toler-
ance criteria. Concerning parotids, the gland volume
included in the PTV was in average 6 ± 8% with a maxi-
mum value of 19% (this small overlap is mainly due to
the CTV to PTV margin, being only of 3 mm. Moreover
it is an internal rule to eventually reduce this margin
toward parotids if judged clinically acceptable); one par-
otid over all glands of all patients was excluded from
the analysis having 40% of its volume inside the PTV: in
this case it was not considered in the optimisation pro-
cess to not compromise the target coverage. In average
the parotid objectives were largely satisfied, except for
three cases, where the mean dose was higher than 30Gy,
with only one of those having also V30Gy higher than
the goal of 45%, being of 50%. In table 3 data for both
structures, Parotid and Parotid-PTV are reported for
completeness. Oral cavity and larynx for Group A+B
fulfilled widely the requested objectives. For optical
apparatus (eyes, optic nerves and chiasm) in Group C
patients, the goals were achieved except in one case,
where the tolerance values exceeded by about 15%.
Concerning Healthy Tissue, a higher dose bath is
delivered to Group A+B patients than Group C, due to
higher dose prescriptions, and more difficult target
shape, with strong concavities, present in the first
group. This is confirmed by the higher CI reported for
Groups A and B with respect to Group C.
Technical parameters of the treatments are summar-
ized in table 4: more than 70% of the cases were planned
with 2 arcs, but keeping the average delivery time below
2m i n .I n d e e dt h ed o s er a t ew a st h ed o s em o d u l a t i n g
parameter, being well below 600 MU/min (and conse-
quently the gantry speed was at its maximum value of 4.8
degree/sec). In a large portion of cases the arcs were not
set as whole rotation (mean arc length was 312 ± 42
degree), also to avoid, in the most posterior entries, the
moving rails that are present in the treatment couch, and
that were always positioned to their most internal setting.
Pre-treatment quality assurance of RapidArc arcs
resulted in an average gamma agreement index GAI of
Figure 2 First row: average (over all patients) DVH for CTV and PTV high dose, with 1SD as dotted lines. Second row: average (divided
for groups A and B) DVH for CTV and PTV low dose, with 1SD as dotted lines.
Scorsetti et al. Radiation Oncology 2010, 5:93
http://www.ro-journal.com/content/5/1/93
Page 5 of 1096.7 ± 2.1%, higher than the acceptance threshold of 95%
set as a reference in our institute. In few cases (three with
GAI around 93%, one with GAI 90%) this threshold was
not achieved, but plans were accepted after careful evalua-
tion of the location of the discrepancies, as well as the
measured/calculated dose profiles. The discrepancies were
mainly found in the interleaf regions.
Clinical results
Table 5 reports findings in terms of toxicities. Two
patients were not evaluated, because they had
unplanned treatment interruption due to rapid worsen-
ing of general conditions.
In the group of the analyzed patients, no grade 4 acute
toxicity was observed. The most common acute G3 toxi-
cities were mucositis (28%), followed by dermitis (14%)
and dysphagia (7%). Nevertheless, no patients required
percutaneous gastrotomy or feedings tubes. Stratifying
patients according to chemotherapy modality, patients
treated with Cetuximab presented the majority of G3
toxicities not only for mucositis but also for dermitis
and dysphagia. To notice is the peak of toxicity for
Cetuximab patients, shifted to G2 or G3 (whichever the
toxicity), while for CDDP patients the peak is mainly at
G1. To consider is the fact that patients receiving
Cetuximab had in average a worse performance status
Figure 3 Average DVHs for OARs, with 1SD as dotted lines, divided for Group A+B and Group C.
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of Cetuximab patients was 0.9, with respect to an aver-
age of 0.2 of groups receiving CDDP or no chemother-
apy. Concerning compliance, 43 of 45 patients
completed treatment (treatment interruption occurred
in two patients treated with Cetuximab).
Late toxicity was not assessed in this investigation
because of short follow-up. Preliminary clinical results are
here reported: at first evaluations, after 2 and 6 months, 31
patients were followed, while 30% of the initial 45 patients
had not first evaluation. Twenty-three patients presented
complete remission (74%), 5 presented partial remission
(16%), and 3 presented stable disease (10%), according to
WHO of Response Evaluation Criteria in solid Tumors-
RECIST-Group. To underline is that 100% of patients who
received CDDP presented complete remission, while this
occurred to 56% of patients treated with Cetuximab.
Discussion
The initial experience of the Istituto Clinico Humanitas
on RapidArc technology applied to 45 head and neck
patients confirmed the findings of good dosimetric
results and of toxicity, as well as the reliability and
efficacy of the RapidArc modality as anticipated in dosi-
metric investigations (19-21).
From the dosimetric viewpoint, presenting Group A+B
a n dG r o u pCd i s t i n c ta n a t o m i cal locations, the analysis
at the level of OARs has been shown separately in order
Table 2 Summary of DVH analysis for PTV
Objective Group A Group B Group C
PTV high
dose
Volume
[cm
3]
142 ± 119 93 ± 68 144 ± 54
Mean [%] 100% 100.2 ± 0.8 100.5 ± 1.0 100.0 ± 0.2
D2% [%] <107% 104.1 ± 2.0 104.0 ± 2.2 104.4 ± 1.7
D5-95%
[%]
Minimise 7.2 ± 2.0 7.0 ± 3.4 7.7 ± 2.7
D98% [%] >95% 94.6 ± 1.5 91.9 ± 6.5 93.6 ± 2.2
V95% [%] 100 97.2 ± 2.0 98.9 ± 1.7 96.5 ± 2.4
V107% [%] 0 0.7 ± 3.2 0.1 ± 0.2 0.4 ± 0.6
CI95% 1 1.21 ± 0.15 1.48 ± 0.43 1.06 ± 0.06
CTV high
dose
Volume
[cm
3]
82 ± 43 59 ± 46 103 ± 41
Mean [%] 100% 100.9 ± 0.6 101.2 ± 1.3 100.6 ± 0.4
D2% [%] <107% 104.0 ± 1.2 104.0 ± 2.1 104.4 ± 1.8
D5-95%
[%]
Minimise 4.6 ± 1.6 4.1 ± 1.8 5.6 ± 2.1
D98% [%] >95% 97.8 ± 1.1 98.3 ± 1.6 96.6 ± 2.0
V95% [%] 100 99.7 ± 0.7 99.6 ± 0.4 99.2 ± 1.1
V107% [%] 0 0.2 ± 0.5 0.1 ± 0.1 0.4 ± 0.6
PTV low
dose
Volume
[cm
3]
253 ± 139 384 ± 282
D98% [%] >95% 95.1 ± 2.4 94.2 ± 2.6
V95% [%] 100 97.1 ± 5.0 97.8 ± 1.1
CI95% 1 1.38 ± 0.16 1.55 ± 0.20
CTV low
dose
Volume
[cm
3]
184 ± 105 264 ± 178
D98% [%] >95% 100.7 ± 2.8 99.8 ± 2.1
V95% [%] 100 99.0 ± 4.0 99.7 ± 0.3
Table 3 Summary of DVH analysis for OARs
Objective Group A+B Group C
Spinal Cord
D1% [Gy] 46Gy 37.7 ± 6.8
[max 44.2]
22.5 ± 19.8
[max 39.7]
Brain Stem
D1% [Gy] 54Gy 25.5 ± 13.0
[max 49.4]
30.2 ± 12.4
[max 48.7]
Parotid
Volume [cm
3]2 1 ± 7 2 4 ± 9
Mean [Gy] <26Gy 21.5 ± 6.4
[max 38.2]
14.7 ± 10.2
[max 25.9]
V30Gy [%] <45% 24.4 ± 13.7
[max 64.6]
10.5 ± 11.8
[max 26.7]
Parotid-PTV
Volume [cm
3]2 0 ± 7 2 4 ± 1 0
Mean [Gy] <26Gy 19.7 ± 5.6
[max 36.4]
13.8 ± 9.3
[max 25.0]
V30Gy [%] <45% 20.4 ± 11.9
[max 61.9]
8.0 ± 8.6
[max 16.8]
Oral Cavity
Mean [Gy] 28.3 ± 9.8
[max 40.8]
V40Gy [%] <50% 20.0 ± 15.7
[max 43.2]
Larynx
Mean [Gy] 34.9 ± 6.4
[max 44.3]
V40Gy [%] <50% 26.6 ± 14.6
[max 42.8]
Eyes
Mean [Gy] 23.5 ± 8.8
[max 43.6]
V40Gy [%] <50% 10.1 ± 17.5
[max 57.1]
Optic Nerves
D1% [Gy] <50Gy 46.7 ± 6.8
[max 56.3]
Chiasm
D1% [Gy] <50Gy 40.7 ± 9.0
[max 47.4]
Healthy tissue
Volume [dm
3] 12.57 ± 4.56 11.40 ± 6.42
Mean [Gy] 6.4 ± 2.9 4.4 ± 2.2
V5Gy [dm
3] 3.21 ± 1.42 2.36 ± 1.18
V10Gy [dm
3] 2.45 ± 1.12 1.73 ± 1.00
EI100% 0.53 ± 1.26 0.80 ± 0.90
DoseInt [Gy dm
3] 72.87 ± 25.23 42.78 ± 26.02
Dx% = dose received by the x% of the volume; Vx% = volume receiving at
least x% of the prescribed dose; CI = ratio between the patient volume
receiving at least 95% of the prescribed dose and the volume of the total
PTV. DoseInt = Integral dose, [Gy cm
3 10
3].
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general conclusion of a safe sparing of the parotids for
Group A+B is supported, being the mean dose was well
below the threshold proposed by Eisbruch et al (24) of
26Gy (and subsequent studies (4, 5)). This would sug-
gest an acceptable degree of xerostomia with related
acceptable quality of life, with good probability of a sub-
stantial preservation of the saliva flow rate. Published
examples of clinical experience with IMRT, such as e.g.
de Arruda et al (25), Chao et al (26), and Eisbruch et al
(24), show improvement of this parotid related para-
meter, with values of 25 ± 4 Gy.
The intensity modulated techniques - fixed gantry
fields and modulated arcs - allowed, since their initial
appearance, the treatment of SIB with the therapy deliv-
ered to various dose levels with the same plan. The
increase in dose/fraction for the high dose level does
not correspond to an increase of dose to the OARs (27).
This opportunity is widely used for head and neck
cancers, differentiating the high risk, intermediate (if
any), and low risk of recurrence.
The usage of one or two arcs is related especially to
the target and patient anatomy complexity. Generally,
with SIB approach, the usage of two arcs is preferable,
as also pointed out by Verbakel et al (19) to improve
target dose homogeneity and Vanetti et al (20) to
improve OARs sparing. In our patient population about
two third received two arcs. The small extra time
needed to re-program the linac for the second arc, and
to deliver the second arc (generally less than 74 sec) is
anyway largely inferior to the time needed to deliver
such treatments with IMRT. For example a dual arc
RapidArc treatment takes about three minutes, while a
seven fixed gantry IMRT fields (often splitted) takes
approximately 15 minutes to be delivered. This, in
terms of patient comfort under the fixation mask, is one
of the significant advantages in using the RapidArc tech-
nology for head and neck patients. With RapidArc treat-
ment those patients can be easily treated with good
dose distributions in a time slot of 10 minutes, including
also the time needed to perform a good imaging
through a 2D-2D matching (with kV-kV or kV-MV
images) or a CBCT. At Istituto Clinico Humanitas a
CBCT is acquired before every fraction, keeping the
time slot of 10 minutes, following specific internal pro-
tocol of quality assurance in terms of patient position-
ing. This procedure gives confidence in patient
treatments allowing the usage of rather small CTV to
PTV margins. Moreover, in the head and neck region,
clinicians can easily detect tumour variations of the
patient volume and anatomy.
In terms of planning time, it could be roughly esti-
mated in about one hour for RapidArc (those have not
to be considered as definitive time values because they
are dependent on planner, usage of pre-defined objective
templates, hardware performances), or half an hour for
IMRT with fixed gantry entrances. To consider in the
frame of time spent to the treatment preparation there
is also the pre-treatment QA process that, with respect
to IMRT, has for RapidArc a shorter time due to the
limited number of arcs or fields to check.
With respect to pre-treatment QA, head and neck
p l a n sw i t hR a p i d A r cs h o w e dt ob er e l i a b l ei nt e r m so f
dose calculation, being within tolerance in the majority
of the cases. The here shown data are coherent with
what reported in literature for the pre-clinical planning
studies, where also some findings concerning delivery
was reported. For example the study on head and neck
cases published by Verbakel et al (19) showed agree-
ment higher than 97% using films and gamma criteria of
DTA = 2 mm and ΔD = 3%; Nicolini et al (28) reported
agreement around 99% for the same criteria adopted in
the present study, using both GLAaS method and
Table 4 Technical characteristics of RapidArc plans
Number of arcs 1 (13), 2 (32)
Arcs length [˚] 312 ± 42
Beam energy 6 MV
Delivery time [min] 1.80 ± 0.62
MU/fraction 458 ± 112
MU/Gy 219 ± 51
Dose Rate [MU/min] 264 ± 88
Gantry speed [deg/sec] 4.8 ± 0.0
Collimator angle [˚] (±)17 ± 6
Mean leaf aperture [cm] 3.0 ± 0.8
Mean CP area [cm
2] 44.0 ± 16.8
Mean field area [cm
2] 219 ± 93
Gamma Agreement Index 3%,3 mm [%] 96.7 ± 2.1 [90.1, 99.7]
MU: monitor units, CP: control point.
Table 5 Acute toxicity
All No chemoth. CDDP Cetuximab
Group A
B
C
36
3
6
4
1
5
13
2
1
19
0
0
Completion of RT Completed
Interrupted
43
2
10
0
16
0
17
2
Mucositis G0
G1
G2
G3
6
17
8
12
5
3
1
1
1
9
4
2
0
5
3
9
Dermitis G0
G1
G2
G3
6
20
11
6
6
3
1
0
0
13
3
0
0
4
7
6
Dysphagia G0
G1
G2
G3
10
11
19
3
5
2
2
1
3
6
7
0
2
3
10
2
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Page 8 of 10Seven29 2D-array (PTW) inside the Octavius phantom
for RapidArc bilateral breast cases. Concerning the here
presented clinical cases, the average GAI of almost 97%
demonstrates the robustness of the delivery in a clinical
environment. As described in the Result section, the few
cases out of the acceptability level were deeply and criti-
cally analyzed and understood before treating the
patients. To notice is the locations of the failing points,
being in the interleaf spaces, where the high resolution
of the detector (EPID) emphasizes the difficulties of the
treatment planning system in properly manage the inter-
leaf leakage and tongue and groove effect. It is also for
this reason that the collimator is rotated during the arc,
in order to smear the effect inside the patient without
causing any valuable effect in terms of dose distribution.
On the clinical side data are here reported on acute
side effects for patients treated with RapidArc with or
without chemotherapy, and on early and preliminary
results on local control.
All patients completed RT treatment, except two cases
that started in bad general conditions at enrolment; eval-
uating concomitant chemo-radiotherapy, all patients
received the planned number of chemotherapy cycles.
Only in the group of patients receiving Cetuximab there
were treatment breaks, but not longer than one week.
Low grade of mucositis and dermitis, and moderate
grade of dysphagia were the most prevalent acute toxici-
ties, whereas mucositis severe enough to necessitate gas-
trotomy or feeding tube were not present. Data regarding
the prevalent toxicities in Cetuximab’sp a t i e n t sm u s tb e
read considering that patients with a low performance
status or unfit were enrolled to receive Cetuximab.
Often high grade acute toxicities do not allow complet-
ing the planned concomitant treatment. With the advent
of IMRT, the possibility to obtain highly conformal dose
distributions around the tumour volume, while sparing
the nearby sensitive structures has greatly improved. The
question of whether this dosimetric improvement creates
less acute toxicities remains open. By our experience,
RapidArc is able to determine low grade acute side
effects and permits to associate concomitant chemother-
apy. Excluding dose painting impact of IMRT, in redu-
cing OAR involvements as well as acute toxicities,
another possible reason of high tolerability in our patient
population could be ascribed to the intense frequency of
clinical controls during treatments. It is an our policy to
check patients more than once per week in order to
detect acute side effects as early as possible and prescribe
personalized supportive care during radio-chemotherapy,
also avoiding or minimizing interruptions.
Conclusion
Forty-five patients presenting head and neck cancer
were treated with Volumetric Modulated Arc Therapy
according to the RapidArc implementation at Istituto
Clinico Humanitas during 2009. Quality of treatments
resulted in a general fulfilment of planning objectives.
Clinical outcome for early acute toxicity showed, as
expected, higher toxicity levels for skin and mucosa
reactions in patients receiving concomitant Cetuximab
chemotherapy. Future investigations will aim to assess at
long term definitive outcome, having this first phase
achieved the primary goal to demonstrate safety and
efficacy of RapidArc.
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